The above-mentioned values are in accordance with a systematic review of 28 articles that stated that positive CD30 expression in DLBCL varied in the range of 3.5% to 59.1% at a cut-off of >0% and ranged from 2.5% to 36.7% at a cut-off of >20% [15]. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.